For instance, in cholangiocarcinoma, IL‐6 inhibition has been shown to counteract gemcitabine resistance by suppressing STAT3 activation driven by IL‐6–producing cancer‐associated fibroblasts [28]. This evidence concerns the gene IL6 and cholangiocarcinoma.